Humacyte, Inc. (HUMA) News

Humacyte, Inc. (HUMA): $3.19

0.06 (+1.92%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add HUMA to Watchlist
Sign Up

Industry: Biotech


Ranked

of 402

in industry

Filter HUMA News Items

HUMA News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

HUMA News Highlights

  • For HUMA, its 30 day story count is now at 2.
  • Over the past 7 days, the trend for HUMA's stories per day has been choppy and unclear. It has oscillated between 1 and 1.

Latest HUMA News From Around the Web

Below are the latest news stories about HUMACYTE INC that investors may wish to consider to help them evaluate HUMA as an investment opportunity.

Humacyte Publication in the Journal of Vascular Surgery – Vascular Science Reports the Human Acellular Vessel™ (HAV™) Remains Durable at Six Years in Patients with Peripheral Artery Disease

- HAVs observed to provide long-term perfusion to patients with critical limb ischemia - 3D Angiograms show mechanical durability of engineered human blood vessels DURHAM, N.C., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissues and advanced tissue constructs and organ systems at commercial scale, today announced the publication of “6-Year Outcomes of a Phase 2 Study of Hu

Yahoo | January 24, 2023

Sidoti's January Micro-Cap Conference

Sidoti & Company, LLC has released the presentation schedule and weblinks for its two-day January Micro-Cap Conference taking place Wednesday and Thursday, January 18-19, 2023.

Yahoo | January 17, 2023

Insider Alert: An Insider Just Sold Humacyte Inc Shares

Related Stocks: HUMA ,

GuruFocus | December 20, 2022

Was anything negative for Humacyte Inc. (HUMA) stock last session?

Humacyte Inc. (NASDAQ:HUMA) closed Monday at $2.21 per share, down from $2.49 a day earlier. While Humacyte Inc. has underperformed by -11.24%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, HUMA fell by -74.63%, with highs and lows ranging from $9.13 to $2.47, whereas the simple […]

US Post News | December 20, 2022

Humacyte''s Return on Invested Capital Insights

Humacyte (NASDAQ: HUMA ) brought in sales totaling $31 thousand during Q3 according to data provided by Benzinga Pro . However, earnings decreased 168.57%, resulting in a loss of $25.28 million. In Q2, Humacyte earned $36.87 million and total sales reached $1.30 million. What Is ROIC? Earnings data without context is not clear and can difficult to base trading decisions on. Return on Invested Capital (ROIC) helps to filter signal from noise by measuring yearly pre-tax profit relative to invested capital by a business. Generally, a higher ROIC suggests successful growth of a company and is a sign … Full story available on Benzinga.com

Benzinga | December 19, 2022

Humacyte Inc. (NASDAQ: HUMA): Surviving A Volatility

Humacyte Inc. (NASDAQ:HUMA) price closed lower on Friday, December 16, dropping -4.23% below its previous close. A look at the daily price movement shows that the last close reads $2.60, with intraday deals fluctuated between $2.47 and $2.67. The company’s P/E ratio in the trailing 12-month period read 7.55. Taking into account the 52-week price … Humacyte Inc. (NASDAQ: HUMA): Surviving A Volatility Read More »

Stocks Register | December 19, 2022

Humacyte Hosting Key Opinion Leader Webinar on Vascular Trauma: Ukrainian Surgeons Discuss Use of Human Acellular Vessels™ (HAV™) in Wartime

Thursday, December 15, 2022 @ 8:00 AM ET Thursday, December 15, 2022 @ 8:00 AM ET

GlobeNewswire | December 13, 2022

Humacyte Hosting Key Opinion Leader Webinar on Vascular Trauma: Ukrainian Surgeons Discuss Use of Human Acellular Vessels (HAV) in Wartime

Thursday, December 15, 2022 @ 8:00 AM ET DURHAM, N.C., Dec. 13, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced that it will host a key opinion leader (KOL) webinar on its proprietary Human Acellular Vessels (HAV) in the treatment of wartime

Wallstreet:Online | December 13, 2022

Humacyte (HUMA) nvestor Presentation - Slideshow (NASDAQ:HUMA)

The following slide deck was published by Humacyte, Inc.

Seeking Alpha | December 8, 2022

Sidoti's December Small-Cap Virtual Conference

Sidoti & Company, LLC has released the presentation schedule and weblinks for its two-day December Small-Cap Conference taking place Wednesday and Thursday, December 7-8, 2022.

Yahoo | December 6, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5123 seconds.